News

10:52 PMYahoo Finance

IBRX stock eyes worst week in nearly 2 years — but Anktiva’s Sepsis Trial Potential fuels Retail bets on big Pharma Appeal

IBRX−9.1%

9:15 PMYahoo Finance

What could ImmunityBio (IBRX) gain from ANKTIVA Label Expansion and Global Rollout?

IBRX−9.1%

8:30 AMYahoo Finance

New U.S. Survey of military service members and veterans with Non-Muscle Invasive bladder cancer reveals 53% were diagnosed at Age 50 or Younger and Barriers to Care

IBRX−9.1%

9:31 PMYahoo Finance

ImmunityBio to Participate in UK investor Conferences during London Life Sciences week 2026

IBRX−9.1%

9:03 AMYahoo Finance

IBRX Q3 earnings miss, Anktiva sales decline Q/Q, stock down 18%

IBRX−9.1%

3:38 PMYahoo Finance

Why ImmunityBio stock dropped 15% after earnings despite 53% sales growth. Is IBRX now a buy?

IBRX−9.1%

11:44 AMYahoo Finance

ImmunityBio shares slump 19% as revenue misses and going-concern warning hits sentiment

IBRX−9.1%

9:36 AMYahoo Finance

IBRX stock crashes to near 9-month lows on Q3 earnings miss – Retail says no way to Escape further dilution

IBRX−9.1%

7:50 AMYahoo Finance

ImmunityBio (IBRX) reports Q3 loss, misses revenue estimates

IBRX−9.1%

7:30 AMYahoo Finance

ImmunityBio reports Label Expansion and Additional Global approval with Q3 2026 Net Product revenue of $48.7 million, up 53% year-over-year and first Nine months U.S. Revenue up 92% to $143.6 million

IBRX−9.1%

7:00 AMYahoo Finance

ImmunityBio and Rafa Announce Israeli Ministry of Health approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive bladder cancer with Carcinoma in Situ

IBRX−9.1%

6:30 AMYahoo Finance

ImmunityBio announces ANKTIVA® Plus BCG Meets Primary endpoint in BCG-Naïve Non-Muscle Invasive bladder cancer randomized QUILT-2.005 trial

IBRX−9.1%

3:33 AMYahoo Finance

Barclays, Deutsche Bank Reveal Stakes in Retail-Favorite Cancer stocks SLS, IBRX and IOVA — Geode adds more

IBRX−9.1%IOVA−5.7%SLS−4.6%

8:00 AMYahoo Finance

ImmunityBio announces first patients in Europe treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive bladder cancer with Carcinoma in Situ

IBRX−9.1%